Rockwell Medical Inc (RMTI) Latest Earnings Release Tops EPS By $0.01

Rockwell Medical Inc (RMTI) announced its most recent quarterly financial results on Wednesday, Mar-15-2017. RMTI said it had a profit of $-0.10 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.01. Analysts had a consensus of $-0.11. The company posted revenue of $13.39 million in the period, compared to analysts expectations of $15.45 million. RMTI’s revenue was down -5.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.12 EPS.

Several company insiders have filed Insider transactions , on Nov 14, 2016, Kenneth L Holt (director) sold 19,725 shares at $5.29 per share price. According to the SEC, on Dec 8, 2015, Ronald D Boyd (director) sold 12,500 shares at $10.59 per share price. On Aug 14, 2015, Robert L Chioini (CEO) purchased 4,910 shares at $11.96 per share price, according to the Form-4 filing with the securities and exchange commission.

Rockwell Medical Inc opened for trading at $5.49 and hit $5.63 on the upside on Wednesday, eventually ending the session at $5.6, with a gain of 2.00% or 0.11 points. The heightened volatility saw the trading volume jump to 3,15,857 shares. Company has a market cap of $289 M.

Rockwell Medical Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency secondary hyperparathyroidism and hemodialysis. The Company’s lead branded drug Triferic is approved by the United States Food and Drug Administration (FDA). Triferic is an iron compound that is delivered to hemodialysis patients via dialysate replacing the iron loss that occurs during their dialysis treatment. Triferic enters the blood and immediately binds to transferrin and is transported to the erythroid precursor cells to be incorporated into hemoglobin. Rockwell’s generic drug Calcitriol is indicated for treating secondary hyperparathyroidism in dialysis patients. The Company manufactures sells delivers and distributes hemodialysis concentrates along with a range of ancillary products.

Rockwell Medical Inc

Leave a Reply

Your email address will not be published. Required fields are marked *